H2BC5: A Potential Drug Target and Biomarker (G3017)
H2BC5: A Potential Drug Target and Biomarker
Hepatic cancer is a leading cause of morbidity and mortality worldwide, with an estimated 8.4 million new cases and 6.1 million deaths in 2019, according to the World Cancer Research Fund (WCRF). Despite advances in cancer treatment, the survival rate forhepatocellular carcinoma (HCC) remains poor, with a five-year survival rate of only 5% to 6%. Therefore, there is a significant need for new treatments and biomarkers to improve outcomes for patients with HCC.
One potential drug target and biomarker that has gained attention in recent years is H2BC5. H2BC5 is a protein that is expressed in the liver and has been shown to be associated with various diseases, including cancer. Specifically, H2BC5 has been shown to be overexpressed in HCC, and high expression levels have been associated with poor prognosis in patients with HCC.
In addition to its potential as a drug target, H2BC5 has also been identified as a potential biomarker for HCC. H2BC5 has been shown to be a reliable biomarker for HCC, with higher expression levels of H2BC5 associated with more aggressive tumors. This suggests that H2BC5 may be a useful target for cancer diagnostics and treatments.
The potential drug target for H2BC5 is related to its role in the development and progression of cancer. Specifically, H2BC5 has been shown to be involved in the regulation of cell growth and has been shown to promote the growth and survival of cancer cells. Therefore, drugs that target H2BC5 may be effective in inhibiting the growth and survival of cancer cells.
One of the first drugs that was shown to target H2BC5 was the drug sorafenib, which is a small molecule inhibitor of the H2BC5 gene. In a clinical trial, sorafenib was shown to be effective in slowing the growth of HCC tumors and improving survival in patients with HCC.
Another drug that has been shown to target H2BC5 is the drug lenvatanib, which is a tyrosine kinase inhibitor. In a clinical trial, lenvatanib was shown to be effective in slowing the growth of HCC tumors and improving survival in patients with HCC.
In addition to these drugs, there are also other potential drugs that may target H2BC5 as a drug. For example, a small molecule inhibitor of the H2BC5 gene, IDH1, has been shown to be effective in slowing the growth of HCC tumors in preclinical studies. Another potential drug that may target H2BC5 is a monoclonal antibody that targets the H2BC5 protein.
While there is currently no approved drug for H2BC5-positive HCC, targeting this protein as a drug target and biomarker may be a promising strategy for the development of new treatments for HCC. With further research, it is possible that these drugs, or other drugs, may become effective in targeting H2BC5 and improving outcomes for patients with HCC.
In conclusion, H2BC5 is a protein that has been shown to be associated with various diseases, including cancer. In addition to its potential as a drug target, H2BC5 has also been identified as a potential biomarker for HCC. Further research is needed to understand the full role of H2BC5 in the development and progression of HCC, as well as the potential utility of drugs that target this protein. These studies may lead to new and effective treatments for
Protein Name: H2B Clustered Histone 5
Functions: Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling
The "H2BC5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about H2BC5 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
H2BC6 | H2BC7 | H2BC8 | H2BC9 | H2BP1 | H2BP2 | H2BP3 | H2BW1 | H2BW2 | H2BW4P | H3-3A | H3-3B | H3-4 | H3-5 | H3-7 | H3C1 | H3C10 | H3C11 | H3C12 | H3C13 | H3C14 | H3C15 | H3C2 | H3C3 | H3C4 | H3C6 | H3C7 | H3C8 | H3P16 | H3P36 | H3P37 | H3P44 | H3P5 | H3P6 | H4C1 | H4C11 | H4C12 | H4C13 | H4C14 | H4C15 | H4C16 | H4C2 | H4C3 | H4C4 | H4C5 | H4C6 | H4C7 | H4C8 | H4C9 | H6PD | HAAO | HABP2 | HABP4 | HACD1 | HACD2 | HACD3 | HACD4 | HACE1 | HACL1 | HADH | HADHA | HADHAP1 | HADHB | HAFML | HAGH | HAGHL | HAGLR | HAGLROS | HAL | HAMP | HAND1 | HAND2 | HAND2-AS1 | HAO1 | HAO2 | HAO2-IT1 | HAP1 | HAPLN1 | HAPLN2 | HAPLN3 | HAPLN4 | HAPSTR1 | HAR1A | HAR1B | HARBI1 | HARS1 | HARS2 | HAS1 | HAS2 | HAS2-AS1 | HAS3 | HASPIN | HAT1 | HAUS1 | HAUS1P1 | HAUS2 | HAUS3 | HAUS4 | HAUS5 | HAUS6
